Abstract 168P
Background
China accounts for half of new esophageal cancer (EC) cases in the world. Limited new therapies were developed during the past decades until the advent of immuno-oncology (IO) in 2020. Yet real-world data is scarce for Chinese EC patients prior to IO approval. This nationwide multicenter retrospective study aimed to describe clinical features and treatment patterns of EC in China to capture baseline treatment landscape as the benchmark before IO approval.
Methods
Patient-level data of patients who initiated first therapy for newly diagnosed EC in 2018 were extracted from a large nationwide database. Information within 6 months after initial anti-tumor treatment were obtained and descriptively summarized.
Results
A total of 3493 EC patients from 14 hospitals in China were included in this study, with mean age of 64.1 years at initial diagnosis. The majority of patients were male (75.7%), squamous cell carcinoma (92.8%), with primary lesion at middle (56.4%) esophagus and living in urban area (53.4%). The proportion of stage I, II and III and IV was 14.9%, 31.6%, 39.2%,14.2%, respectively. Out of the 2138 resectable patients, 1986 underwent upfront radical surgery, while 7.1% patients received neoadjuvant therapy, among which chemotherapy was mainstay preoperative therapy (85.5%). Twenty-three percent of resectable patients had adjuvant therapy, with chemotherapy as the mainstream (75.2%) postoperative regimen. For unresectable early and locally advanced patients, the percentage of radical therapy and palliative therapy was 49.9% and 50.1%, respectively, and definitive chemoradiotherapy was the most common treatment (32.0%). For advanced stage patients, chemotherapy accounted for 84.3% of upfront therapy and taxane-based chemotherapy regimen predominated (66.2%).
Conclusions
In this large observational study, most early-stage and locally advanced patients underwent upfront surgery without preoperative treatment, while for advanced patients, chemotherapy was the primary choice. This is the first real-world study of EC to date with largest sample size reflecting Chinese treatment landscape before IO approval, which will help address unmet needs in clinical practice.
Clinical trial identification
EU PAS Register Number: EUPAS48396, release on 29/07/2022.
Editorial acknowledgement
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. MSD China holding.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure
D.F. Shi, Q. Jing, S. Shi, F. Dong: Financial Interests, Personal, Full or part-time Employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract